Last reviewed · How we verify
Reference treatment : Nicotine transdermal patch
At a glance
| Generic name | Reference treatment : Nicotine transdermal patch |
|---|---|
| Sponsor | Pierre Fabre Medicament |
| Modality | Small molecule |
| Phase | Phase 1 |
Approved indications
Common side effects
Key clinical trials
- Health Systems Reach Interventions Project (PHASE4)
- Effectiveness of Combined Tobacco Treatment in Hospitalized Subjects (PHASE4)
- Transdermal Patch CVD 1000: The Effect of Heat on Nicotine Release From Nicotine Patches in Adult Smokers (PHASE4)
- Autonomic Nervous Activity During the Systemic Inflammatory Response in Trained and Untrained Healthy Volunteers (EARLY_PHASE1)
- Nicotine Patch - Bioequivalence Study (PHASE1)
- Nicotine Patch Bioequivalence Study (PHASE1)
- Nicotine Patch - Multidose Bioequivalence Study (PHASE1)
- Nicotine Patch Safety Study (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape: